Your browser is no longer supported. Please, upgrade your browser.
APM Aptorum Group Limited daily Stock Chart
Aptorum Group Limited
Index- P/E- EPS (ttm)-0.13 Insider Own29.39% Shs Outstand29.10M Perf Week1.76%
Market Cap487.12M Forward P/E- EPS next Y-0.42 Insider Trans- Shs Float4.13M Perf Month4.62%
Income-18.40M PEG- EPS next Q- Inst Own0.20% Short Float0.36% Perf Quarter-34.86%
Sales0.60M P/S811.87 EPS this Y-462.50% Inst Trans20.75% Short Ratio3.84 Perf Half Y27.39%
Book/sh0.86 P/B19.46 EPS next Y- ROA- Target Price28.50 Perf Year-
Cash/sh0.22 P/C77.32 EPS next 5Y- ROE- 52W Range11.80 - 33.28 Perf YTD10.27%
Dividend- P/FCF- EPS past 5Y- ROI-23.80% 52W High-49.70% Beta-
Dividend %- Quick Ratio12.90 Sales past 5Y- Gross Margin-11.70% 52W Low41.86% ATR0.56
Employees39 Current Ratio13.00 Sales Q/Q799.40% Oper. Margin- RSI (14)44.43 Volatility2.77% 2.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-45.60% Profit Margin- Rel Volume0.35 Prev Close16.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.92K Price16.74
Recom2.00 SMA202.07% SMA50-9.61% SMA200-7.83% Volume1,374 Change-0.24%
Sep-19-19 08:10AM  Aptorum Group Limited's (NASDAQ:APM) Single Biggest Risk For Investors Simply Wall St.
Sep-09-19 06:34AM  Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma Business Wire
06:00AM  Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019 Business Wire
06:00AM  Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA Business Wire
Jul-11-19 08:00AM  Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform Business Wire
Jul-08-19 08:00AM  Aptorum Groups subsidiary Smart Pharma announces Smart Pharma token (SMPT) to be listed on IDAX and LATOKEN Business Wire
Jun-26-19 11:05AM  APM: Aptorum Focused on Development of Diseases with Significant Global Unmet Needs Zacks Small Cap Research
May-22-19 08:00AM  Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index Business Wire
May-15-19 09:00PM  Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States Business Wire
May-07-19 07:19AM  What Percentage Of Aptorum Group Limited (NASDAQ:APM) Shares Do Insiders Own? Simply Wall St. +10.76%
May-06-19 08:00AM  Aptorum Groups Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various Diseases via Modulation of the Chemical Signaling Relating to Gut Microbiota Business Wire
Apr-30-19 10:42AM  UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM) GlobeNewswire
Apr-24-19 08:00AM  USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations Business Wire
04:30AM  Aptorum Groups Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT Business Wire
04:30AM  Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases Business Wire
04:15AM  Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019 Business Wire
Apr-15-19 09:55AM  Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update Business Wire
Apr-01-19 09:30AM  Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer Business Wire
Mar-08-19 02:49PM  Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019 Business Wire
Mar-04-19 11:26AM  Aptorum Group Limited to Present at the Barclays Global Healthcare Conference 2019 Business Wire
Feb-25-19 05:28AM  BRIEF-APM Automotive Posts Qtrly Net Profit Of 17.3 Million RGT Reuters
Dec-07-18 02:07AM  Aptorum Group Limited Announces Pricing of Initial Public Offering Business Wire
Feb-28-18 05:20AM  BRIEF-APM Automotive Holdings Posts Qtrly Net Profit 13.1 Million RGT Reuters
Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The company also focuses on the development of surgical robotics and medical devices; and operating outpatient clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in Central, Hong Kong.